Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Register for Details

For more details on financing and valuation of private companies similar to Alto Neuroscience before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Alto Neuroscience

To invest in Alto Neuroscience pre-IPO

Can you invest in Alto Neuroscience pre-IPO?

You may invest in Alto Neuroscience as it is a public company listed on the NASDAQ with ticker ANRO. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Alto Neuroscience before it goes public?

You can no longer sell shares of Alto Neuroscience on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Alto Neuroscience shares?

Forge can no longer determine the value of Alto Neuroscience shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Alto Neuroscience a publicly traded company?

Alto Neuroscience became a public company following its IPO on 02/02/2024 and is now traded on the NASDAQ under the ticker ANRO.

To learn more about Alto Neuroscience potential IPO

Will Alto Neuroscience go IPO?

Alto Neuroscience became a public company following its IPO on 02/02/2024 and is now traded on the NASDAQ under the ticker ANRO.

What is Alto Neuroscience’s IPO price?

The IPO price of Alto Neuroscience is not currently available.

When was Alto Neuroscience founded?

Alto Neuroscience was founded in 2019.

What is Alto Neuroscience funding to date?

Alto Neuroscience has raised $253.17MM to date.

Who are Alto Neuroscience’s major investors?

Valor Equity Partners
Gaingels
Vine Ventures
Point72 Ventures
What If Ventures
Novartis
NJF Capital
National Institutes of Health
Windham Venture Partners
Sobrato Capital
Korify Capitals
Alpha Wave Global
re.Mind Capital
Able Partners
Bioverge Ventures
K2 HealthVentures
InVivium Capital
Lightswitch Capital
Catena Capital
Presight Capital

Alto Neuroscience Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
11/21/2023 Series C $50.31MM $xx.xx $235.65MM Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners
Price per Share
$xx.xx
Shares Outstanding
10,674,967
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners
01/30/2023 Series B $59.26MM $xx.xx $218.32MM Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners
Price per Share
$xx.xx
Shares Outstanding
9,876,955
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners
10/14/2021 Series A $34.08MM $xx.xx $128.77MM Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners
Price per Share
$xx.xx
Shares Outstanding
7,250,992
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners
09/30/2019 Series Seed $7.72MM $xx.xx $30.89MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,708,682
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 3, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.